Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition

Aptevo Therapeutics Inc.

Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.
Expanded CD3 pipeline with three new candidates including first trispecific assets.
Established $60M equity line with Yorkville; supports operations potentially into 2029.
Cash $21.6M at Dec 31, 2025 (up from $8.7M); net loss $26.0M vs $24.1M in 2024.
CEO Marvin White becomes Executive Chair; Jeff Lamothe named President and CEO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.